Certain Dermatological Treatment Devices and Components Thereof II

Serendia, LLC filed a Section 337 complaint targeting imported dermatological treatment devices and components thereof, naming InMode and multiple BTL entities as proposed respondents. The Federal Register notice does not identify the asserted patents; Serendia seeks a limited exclusion order, cease-and-desist orders, and bonding during the Presidential review period. The complaint concerns energy-based or device-based dermatological treatment technology, a commercially significant aesthetics and medical-device market. The Commission is soliciting public-interest comments on potential effects of the requested relief on U.S. public health and welfare, competitive conditions, domestic production of like articles, replacement capacity, and U.S. consumers. Complainant: Serendia, LLC Proposed respondents: InMode Ltd.; Invasix Inc.; BTL Industries, Inc.; BTL Industries Limited; BTL Industries JSC; BTL Healthcare Technologies A/S; BTL Enterprise Group A/S; BTL Medical Technologies S.R.O.; BTL Holding Limited Products targeted: certain dermatological treatment devices and components thereof II Asserted patents: not identified in the Federal Register notice Relief sought: limited exclusion order, cease-and-desist orders, and bond during the 60-day Presidential review period